Impact of HIV and Its Treatment on Reverse Cholesterol Transport
This study has been completed.
Sponsor:
The Alfred
Collaborator:
National Health and Medical Research Council, Australia
Information provided by (Responsible Party):
Jennifer Hoy, The Alfred
ClinicalTrials.gov Identifier:
NCT00168233
First received: September 9, 2005
Last updated: January 19, 2012
Last verified: January 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To investigate the effect of treatment of HIV infection with highly active antiretroviral therapy on individual steps of reverse cholesterol transport, endothelial function and intima-media thickness in HIV patients.
| Condition |
|---|
|
HIV Infections |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Impact of HIV Infection and Treatment With Highly Active Antiretroviral Therapy on Reverse Cholesterol Transport |
Resource links provided by NLM:
Further study details as provided by The Alfred:
| Enrollment: | 44 |
| Study Start Date: | June 2005 |
| Study Completion Date: | March 2011 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
No antiretroviral therapy for 12 months
|
|
2
Initiating ARV therapy with an NNRTI based regimen
|
|
3
Initiating ARV therapy with a PI based regimen
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
HIV infected patients naive to ARV therapy
Criteria
Inclusion Criteria:
- Male patients with HIV infection (3 groups of 50 patients each)
- HIV infected patients, naïve to ARV therapy and not likely to need to commence therapy for the duration of follow-up (12 months)
- HIV-infected patients, PI naïve, initiating therapy with PI-containing HAART (ARV naïve or NNRTI experienced changing to PI regimen)
- HIV-infected patients naïve to ARV therapy, initiating NNRTI-containing regimen
Exclusion criteria
- Treatment with any form of lipid lowering drugs, including fish oils.
- Body Mass Index greater than 27.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00168233
Locations
| Australia, Victoria | |
| Alfred Hospital and Baker Heart Research Institute | |
| Melbourne, Victoria, Australia, 3004 | |
Sponsors and Collaborators
The Alfred
National Health and Medical Research Council, Australia
Investigators
| Study Director: | Dmitri Sviridov, Dr | Baker Heart Research Institute, Commercial Road, Melbourne |
| Principal Investigator: | Jennifer Hoy, A/Prof | Alfred Hospital, Melbourne, Vic 3004 |
More Information
No publications provided
| Responsible Party: | Jennifer Hoy, Professor Jennifer Hoy, The Alfred |
| ClinicalTrials.gov Identifier: | NCT00168233 History of Changes |
| Other Study ID Numbers: | 54/05 |
| Study First Received: | September 9, 2005 |
| Last Updated: | January 19, 2012 |
| Health Authority: | Australia: National Health and Medical Research Council |
Keywords provided by The Alfred:
|
Treatment Naive HIV |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on June 18, 2013